1. Home
  2. ANGO vs PRTA Comparison

ANGO vs PRTA Comparison

Compare ANGO & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ANGO
  • PRTA
  • Stock Information
  • Founded
  • ANGO 1988
  • PRTA 2012
  • Country
  • ANGO United States
  • PRTA Ireland
  • Employees
  • ANGO N/A
  • PRTA N/A
  • Industry
  • ANGO Medical/Dental Instruments
  • PRTA Biotechnology: Pharmaceutical Preparations
  • Sector
  • ANGO Health Care
  • PRTA Health Care
  • Exchange
  • ANGO Nasdaq
  • PRTA Nasdaq
  • Market Cap
  • ANGO 400.8M
  • PRTA 346.4M
  • IPO Year
  • ANGO 2004
  • PRTA N/A
  • Fundamental
  • Price
  • ANGO $9.33
  • PRTA $6.41
  • Analyst Decision
  • ANGO Strong Buy
  • PRTA Buy
  • Analyst Count
  • ANGO 2
  • PRTA 9
  • Target Price
  • ANGO $15.50
  • PRTA $27.67
  • AVG Volume (30 Days)
  • ANGO 570.7K
  • PRTA 1.7M
  • Earning Date
  • ANGO 07-15-2025
  • PRTA 08-07-2025
  • Dividend Yield
  • ANGO N/A
  • PRTA N/A
  • EPS Growth
  • ANGO N/A
  • PRTA N/A
  • EPS
  • ANGO N/A
  • PRTA N/A
  • Revenue
  • ANGO $283,320,000.00
  • PRTA $137,935,000.00
  • Revenue This Year
  • ANGO N/A
  • PRTA N/A
  • Revenue Next Year
  • ANGO $6.35
  • PRTA $122.02
  • P/E Ratio
  • ANGO N/A
  • PRTA N/A
  • Revenue Growth
  • ANGO N/A
  • PRTA 54.55
  • 52 Week Low
  • ANGO $5.67
  • PRTA $4.32
  • 52 Week High
  • ANGO $13.50
  • PRTA $25.42
  • Technical
  • Relative Strength Index (RSI)
  • ANGO 43.45
  • PRTA 57.61
  • Support Level
  • ANGO $9.12
  • PRTA $5.96
  • Resistance Level
  • ANGO $9.78
  • PRTA $6.77
  • Average True Range (ATR)
  • ANGO 0.40
  • PRTA 0.36
  • MACD
  • ANGO -0.09
  • PRTA 0.14
  • Stochastic Oscillator
  • ANGO 26.24
  • PRTA 75.80

About ANGO AngioDynamics Inc.

AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.

About PRTA Prothena Corporation plc

Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.

Share on Social Networks: